Hall 7 (Salle S4, Floor -1)

08:00 - 09:00 BUSINESS MEETING
09:00 - 10:30

Methods corner: Novel interventional studies assessing outcomes in patients with CHD

Chair: Ewa-Lena Bratt, Sweden
Co-chair: Malin Berghammer, Sweden

Neurodevelopmental outcomes,
Johanna Calderon, France
Transition-related outcomes,
Mariela Acuna Mora, Sweden
Lifestyle and behavioral outcomes,
Cristopher McCusker, Ireland
Economic and health policy outcomes,
Ruben Willems, Belgium

10:30 - 11:00 BREAK
11:00 - 12:30

Chair: Skaiste Sendzikaite, Switzerland
Sabrina Bressieux-Degueldre, Switzerland

O-097 Three-dimensional echocardiography and global longitudinal strain in the assessment of left ventricular function in children after PIMS-TS,
Halszka Kamińska, Poland
O-098 Increase in Kawasaki disease incidence observed in 30-year population-based study in Scandinavia,
André Rudolph, Sweden
O-099 Complete resolution of cardiac sequelae is seen in patients treated for paediatric multisystem inflammatory syndrome (PIMS) by 12 months,
Sally Hall, UK
O-100 A comparative study of cardiac involvement of Kawasaki Disease and Multisystem Inflammatory Syndrome post Covid (MISC) in children,
Debadatta Mukhopadhyay, India
O-101 Kawasaki disease in the time of COVID-19 – The International Kawasaki Disease Registry,
Ashraf S Harahsheh, United States
O-102 Anakinra in treatment of Pediatric Inflammatory Multisystem Syndrome Temporally associated with SARS-CoV2 infection (PIMS-TS) with cardiac involvement,
Joanna Lea Friedman Gruszczynska, Poland